A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.
The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.
The firm does not impose strict requirements regarding company structure or management team composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.
The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.
From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
A large multi-stage venture capital and private equity firm manages substantial assets across multiple strategies. The firm recently established a dedicated life sciences investment vehicle focused on global venture, growth-stage, and co-investment opportunities. The strategy operates in partnership with major international healthcare and investment organizations to support long-term value creation and commercialization.
The firm invests broadly across life sciences while expanding its focus into digital healthcare and bio-IT convergence. The strongest areas of interest remain within therapeutics, particularly antibody-drug conjugates (ADC), targeted protein degradation (TPD), and cell and gene therapy. Key therapeutic areas include oncology, metabolic disorders, immunology, and neurology. The firm is also actively evaluating opportunities in AI-enabled healthcare, medical data infrastructure, synthetic biology, next-generation diagnostics, and wearable technologies.
From a company and management team perspective, the firm prioritizes teams with strong scientific and technical expertise. The investment team includes professionals with R&D and clinical development backgrounds who conduct in-depth technical evaluations. Following investment, the firm leverages strategic global partnerships and industry networks to support commercialization, business development, and technology transfer from academic and research institutions. The firm is particularly interested in companies with strong expansion potential or opportunities positioned for strategic or early exit outcomes.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
An early-stage investment and development firm based in the United States operates under an evergreen investment structure. The firm manages substantial long-term capital and maintains flexibility in both investment size and transaction structure. Initial investments typically range from approximately $1M to $10M, with additional reserves available for continued support of successful portfolio companies.
The firm focuses on medical devices and research tools. Within medical devices, the firm prefers technologies pursuing higher-barrier regulatory pathways, including PMA approvals. Within research tools, the firm invests in technologies that enable or enhance the discovery and manufacturing of therapeutics and diagnostics, particularly those with meaningful commercial scalability and strong recurring revenue potential.
From a company and management team perspective, the firm seeks to invest in small, early-stage companies led by lean but highly capable management and execution teams. The firm primarily focuses on opportunities in the United States while remaining open to select opportunities in Europe.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
After securing 1st Place in the Innovator’s Pitch Challenge at RESI Europe, StimOxyGen is gaining momentum as it advances its lead program, SGEN-33, toward clinical development. In this interview, Sian Farrell discusses the science behind the platform, upcoming milestones, and how the RESI experience has accelerated investor engagement.
Caitlin Dolegowski (CD): For those new to StimOxyGen, how would you describe SGEN-33 and the problem it is solving in a way that resonates with investors?
Sian Farrell (SF): SGEN-33 is a pH-responsive, oxygen-generating nanoparticle designed to overcome tumour hypoxia, one of the biggest barriers limiting the effectiveness of radiotherapy and other cancer treatments. Many aggressive solid tumours, particularly pancreatic cancer, are severely oxygen deprived, making them highly resistant to therapy. SGEN-33 selectively activates within the acidic tumour microenvironment, releasing oxygen directly where it is needed to help re-sensitise tumours to treatment. What makes the opportunity particularly compelling is that we are addressing a fundamental biological resistance mechanism that impacts multiple high-value oncology indications. Rather than replacing existing therapies, SGEN-33 is designed to enhance them, positioning StimOxyGen within the growing combination of therapy landscape.
CD: What makes this approach particularly compelling from a commercial and clinical perspective compared to existing strategies?
SF: Clinically, our approach is differentiated because SGEN-33 generates oxygen directly within the tumour microenvironment rather than relying on systemic oxygen delivery methods, which have historically shown limited success. Existing hypoxia-targeting strategies such as hyperbaric oxygen therapy or intratumoural injections face significant limitations in practicality, scalability, or clinical adoption. In contrast, SGEN-33 is designed for intravenous administration and tumour-selective activation, offering a scalable and clinically feasible solution. Commercially, we believe this creates a highly attractive platform opportunity. Radiotherapy is used in approximately 60% of cancer patients worldwide, yet hypoxia remains a major unresolved challenge. By integrating into existing standards of care, SGEN-33 has the potential to enhance multiple treatment modalities across several solid tumour types without requiring clinicians to completely change current workflows. Importantly, we have already demonstrated strong preclinical efficacy and safety data in highly hypoxic tumour models, including pancreatic cancer, triple-negative breast cancer, and aggressive prostate cancer. Our studies have shown significant tumour growth reduction and survival benefit when SGEN-33 is combined with radiotherapy.
CD: What key milestones or inflection points should investors be watching as you move toward clinical development?
SF: The next 18–24 months represent a highly important period for StimOxyGen as we advance SGEN-33 toward clinical development. Our current focus is on completing key IND-enabling activities, including GLP toxicology and DMPK studies, GMP manufacturing scale-up, FDA regulatory engagement, and expansion of our radiotherapy-immunotherapy datasets. Alongside these milestones, we are progressing collaborations with leading translational oncology centres including Memorial Sloan Kettering Cancer Center (MSK), advancing early clinical strategy and trial design activities, and continuing to strengthen our scientific and clinical advisory network. A particularly exciting area is the growing evidence of immune-mediated effects observed in our preclinical studies, which may create future opportunities in combination with immunotherapy approaches.
CD: What are your current fundraising priorities, and what types of investors or partners are you looking to engage at this stage?
SF: We are currently raising $7.5 million to advance SGEN-33 through IND-enabling development and position the programme for First-in-Human clinical studies, with a target close by Q1 2027. The financing will support key value-creation milestones including GLP toxicology, DMPK studies, GMP manufacturing scale-up, FDA regulatory engagement, and continued expansion of our radiotherapy-immunotherapy datasets. In parallel, we are progressing clinical strategy and early trial design activities through collaborations with leading translational oncology centres, including Memorial Sloan Kettering Cancer Center (MSK). We are particularly interested in engaging with specialist life science investors, oncology-focused funds, and strategic partners with expertise in radiotherapy, immuno-oncology, nanomedicine, and translational drug development.
CD: How did participating in RESI Europe and the Innovator’s Pitch Challenge impact your visibility and conversations with investors?
SF: Participating in RESI Europe was hugely valuable for StimOxyGen from both a networking and visibility perspective. Having the conference based in Lisbon created an important opportunity to expand beyond the UK ecosystem and connect more directly with the broader European life science investment community. It allowed us to significantly grow our investor network and establish new relationships with international investors and strategic partners. Winning 1st Place in the Innovator’s Pitch Challenge increased our visibility and credibility within the global biotech community and created strong momentum in investor conversations. An additional benefit is the opportunity to attend future RESI conferences, including events in the United States, which will help us continue expanding our US investor and strategic partner network as we move toward clinical development. Beyond the exposure itself, the experience also provided a significant confidence boost for our team and reinforced that the work we are doing is resonating internationally.
CD: What stood out most about the Innovator’s Pitch Challenge experience compared to other pitch opportunities?
SF: What stood out most was the quality and relevance of the audience. I’ve participated in pitch competitions previously, but many were more sector-agnostic and included a broad mix of industries and technologies. At RESI, it was particularly meaningful to receive recognition in a highly relevant and competitive life sciences environment, surrounded by innovative biotech and healthcare companies tackling major clinical challenges. The discussions also felt far more relationship-driven than transactional. Conversations extended beyond the pitch itself and focused on clinical strategy, regulatory pathways, commercialization, and long-term value creation. Importantly, the support from the Life Science Nation (LSN) team did not feel like a “one-and-done” experience. The ongoing opportunities through future RESI events and the wider LSN network create continued momentum and provide a strong platform for us to further expand our international investor and strategic partner network moving forward.
CD: Following your win, what are the next key priorities for StimOxyGen as you move into your next phase of growth?
SF: Our biggest priority is maintaining the momentum we have built over the past 18 months as we advance SGEN-33 toward clinical development. Since completing our first VC financing round in January 2025, we have continued to de-risk the technology, expand our international investor network, progress collaborations with Memorial Sloan Kettering Cancer Center (MSK), and strengthen our translational and regulatory strategy. Winning the RESI Europe Innovator’s Pitch Challenge was another important milestone that reinforced the growing momentum around the company. Over the next phase of growth, our focus is on advancing SGEN-33 through IND-enabling development, progressing FDA engagement, scaling manufacturing capabilities, and continuing to strengthen our clinical strategy. Of course, securing the capital required to move the programme into the clinic remains a critical priority. We believe StimOxyGen is at a genuinely exciting inflection point, and we are actively looking to partner with investors who share both our ambition and our sense of urgency. At the heart of everything we do is the patient. We are working on therapies for people facing some of the most difficult-to-treat cancers, where treatment options are limited and outcomes remain devastatingly poor. That reality keeps our team focused every day and drives our determination to move as quickly and responsibly as possible toward the clinic. For us, this is about far more than building a company — it is about giving patients and families hope where too often there currently is very little. And, if our story resonates with you, we would love to continue the conversation.
Additional Innovator’s Pitch Challenge (IPC) slots are now available, giving companies the opportunity to pitch directly to investors, receive live feedback, and boost visibility ahead of the event. Applications close May 22.
By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
As part of Life Science Nation’s series on converting scientific innovation into investable signal, the final layer of the De-Risk Stack addresses exit risk. (Explore the full series here) After market, technical, regulatory, execution, economic, and financing risks are reduced, the final question becomes clear: how does this become a return?
Exit Risk
From Story to Outcome
At the top of the stack is the question every investor ultimately asks: how does this become a return?
Exit risk is not about predicting a specific transaction. It is about defining a realistic, evidence-based path to liquidity. Without that, even well-executed companies remain difficult to fund across multiple rounds.
This begins with clarity on the most likely exit path, acquisition, licensing, or public markets, aligned with the type of company you are building and the norms of your sector.
From there, you must be able to name a credible buyer universe: specific pharmaceutical, biotechnology, device, or platform companies for whom your asset would represent strategic value. Strategic fit explains why those buyers should care, how your product fills a pipeline gap, extends an existing franchise, enables a new modality, or provides differentiated access to a market.
Timing and value inflection points determine when the asset becomes relevant to those buyers. Clinical data, regulatory milestones, partnership signals, and early commercial traction all influence when interest peaks.
Competitive positioning answers why your asset would be selected over alternatives. Deal structure reality grounds expectations in how transactions are done in your space, including licensing terms, milestones, royalties, and acquisition patterns.
Finally, return potential must align with the expectations of the capital investing in the company. A good company is not always a good investment. The scale and timing of the likely outcome must match the risk and capital required to get there.
Exit risk is resolved when the company presents a credible path from development to liquidity, with clear buyers, clear triggers, and realistic structures.
Core Elements of Exit Risk
Exit path clarity
Buyer universe
Strategic fit
Timing
Value inflection points
Competitive positioning
Deal structure reality
Return potential
Sequence and Progression
These risks do not resolve independently. The order in which they are addressed determines outcome.
When this sequence is followed, uncertainty is reduced efficiently and value compounds. When it is not, capital is consumed without progress and even strong assets can stall.
From Risk to Signal
The purpose of de-risking is to generate signal.
Investors do not fund ideas; they fund signal, coherent, cross-validated evidence that enough uncertainty has been removed to justify action. Each layer of the stack produces a different class of signal: market signal, technical signal, regulatory signal, execution signal, economic signal, financing signal, exit signal. As these accumulate and align, an opportunity becomes not just understandable, but investable.
Fundraising, in this view, is not persuasion. It is the systematic production and communication of signal.
Implications
For founders, progress is defined by the reduction of uncertainty, not by the volume of activity or the length of the roadmap.
For investors, the De-Risk Stack provides a structured framework for evaluation, what is resolved, what remains unresolved, and what must be proven next.
For ecosystems, it highlights the missing infrastructure between innovation and capital: shared standards, de-risking platforms, and operating systems that help assets move through this process more reliably.
From Framework to System
The De-Risk Stack defines how life science companies become investable. Implementation defines how that process is executed.
At the company level, this means shaping opportunities deliberately, targeting specific layers of risk, executing against clear milestones, and running structured fundraising campaigns.
At the ecosystem level, it means building infrastructure that can systematically identify, assess, and advance assets through the stack, so promising technologies do not stall for avoidable reasons.
When applied consistently, the De-Risk Stack becomes more than a framework. It becomes a system for converting scientific innovation into investable opportunity.
Closing
The challenge in life science is not discovery. It is the disciplined conversion of discovery into investable signal.
An old adage in drug development states that any successful program for an advanced medicine must overcome three central challenges: first, delivery; second, delivery, and third … delivery! Lipid nanoparticle (LNP) technology and N-acetyl galactosamine-(GalNAc) conjugates have opened the liver to a wide range of genetic medicines, and transferrin 1 receptor (TfR1) conjugates are beginning to access the CNS via intravenous delivery with brain-shuttle technology. But tissues like the lung, kidney, muscle and heart remain very much a work in progress.
In the pulmonary space, a small cadre of companies are pursuing inhaled LNP delivery technologies. Recode Therapeutics, Vertex Pharmaceuticals and Arcturus are the main players, while other firms such as 4DMT and Krystal Biotech are focusing on viral gene therapies for lung delivery.
Just a few days ago, one of these LNP programs got the chop. The Vertex/Moderna phase 1/2 study of VX-522, an aerosolized LNP to deliver mRNA encoding full-length cystic fibrosis transmembrane conductance regulator (CFTR) to the lungs of cystic fibrosis patients, which had been paused due to tolerability issues, is now permanently discontinued. According to reports, the Moderna LNP was the culprit, leading to lung inflammation. That leaves Recode and Arcturus as the frontrunners, a rather small field, given the entire market opportunity for a pulmonary delivery solution. All told, in 2023, there were 569.2 million cases of chronic respiratory diseases and 4.2 million deaths from respiratory disease.
Recode now is enrolling patients into the phase 2 trial of its Selective Organ Targeting (SORT), LNP platform (RCT2100) that delivers an mRNA encoding CFTR in combination with the small-molecule CFTR potentiator ivacaftor (the SORT technology was originally licensed out of Daniel Siegwart’s group at UT Southwestern). The other LNP platform, Arcturus’ LUNAR LNP technology, also has encouraging interim data from its phase 2 trial in cystic fibrosis patients and from its program delivering ornithine transcarbamylase mRNA.
These LNPs (and most other LNP delivery platforms) are built around the same four common components: an amino ionizable lipid, a helper lipid, a polyethylene glycol lipid and cholesterol. The formulations follow this scheme but with different combinations of proprietary lipid forms; thus, in Arcturus’ LUNAR LNP, distearoylphosphatidylcholine (DSPC) performs the helper lipid function, whereas in Recode’s SORT LNP, it is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Overall, however, just a handful of novel lipid components have gone into humans so far.
According to Siegwart, the field is in dire need of developing a broader palette of cationic lipids that are both efficient and non-toxic for the pulmonary epithelium; ultimately, the goal would be a delivery technology capable of targeting specific cell types in the lung (with many new cell subtypes continuing to be identified).
The respiratory epithelium contains a diverse set of cell subtypes important in maintaining respiratory homeostasis. Dysfunction in these cells can lead to disease. PNEC, pulmonary neuroendocrine cell; PCD, primary ciliary dyskinesias; CGRP, calcitonin gene related peptide; SIDS, sudden infant death syndrome; SCLC, small cell lung carcinoma; Mtb, Mycobacterium tuberculosis; COPD, chronic obstructive pulmonary disease. Source: Mucosal Immunology
In a recent article in Nature Biomedical Engineering, Siegwart and his group at UT Southwestern introduce the design and evaluation of a new class of lung-targeting (LuT) lipids that enable the highly efficient and selective delivery of mRNA and CRISPR–Cas9 gene-editing systems to the lungs.
They synthesized and screened a library of 444 lipids using a combinatorial approach, systematically varying amine head groups and hydrophobic tails. Through in vivo testing and structure–activity relationship analysis, they identified key features in the lipids that most effectively targeted the lung: a distinctive ‘tripod-like’ structure, consisting of a quaternary amine head, three long alkyl chains and a short fourth chain.
Design, synthesis and multi-round evaluation of LuT lipids for pulmonary delivery. a, LuT lipids were chemically synthesized by one-step combinatorial conjugation of diverse amine heads and alkyl/alkenyl bromide tails, formulated into LuT LNPs and intravenously administrated into mice for in vivo evaluation. SARs governing the function of LuT LNPs were carefully analyzed. b, After in vivo evaluation, the top-performing LuT lipids with a tripod-like structure were identified and showed exceptional mRNA delivery efficiency, which inspired the in-depth investigation into their performance in specific cell type targeting, mechanisms and gene editing. Source: Nature Biomedical Engineering
Compared to benchmark formulations, the best-performing LuT-containing LNPs achieved up to a 25.5-fold increase in mRNA delivery and a 9.2-fold improvement in gene-editing efficiency, with >90% of delivery localized to the lungs. These LuT-LNPs successfully transfected multiple lung cell types, including endothelial, epithelial and immune cells, with some formulations showing preferences for specific cell populations.
Mechanistically, the improved performance was attributable to two main factors. First, the tripod-like structure of lipids promoted endosomal escape by facilitating membrane fusion and LNP disassembly, allowing efficient release of genetic cargo into cells. Second, LuT LNPs formed distinct protein coronas in the bloodstream, particularly enriching for vitronectin, a protein that enhances targeting to lung cells via receptor-mediated uptake.
Siegwart and his team went on to show the therapeutic potential of LuT LNPs. The lead formulation, 1A7B13, enabled effective delivery of IL-10 mRNA in a mouse model of acute lung injury and achieved robust CRISPR–Cas9 gene editing in lung tissue. The LNPs showed minimal toxicity and no significant adverse effects in vivo.
This research establishes clear design principles for lung-targeting LNPs and markedly expands the available toolkit for pulmonary gene delivery. It is just the beginning of the translational path, however.
The Siegwart LuT-LNPs must home through the vasculature to the lungs after being delivered intravenously. This is very different from the aerosolized LNP delivery approaches of Recode and Arcturus currently in clinical testing. There may be a case to be made that some pulmonary vascular disease, lung endothelial targets, lung fibrosis, immune-cell or vascular-compartment targets might warrant the intravenous route, but aerosolized LNP delivery provides lower systemic exposure (and thus higher therapeutic index), is more patient-friendly, and rapidly/directly reaches the airway lumen.
Regardless of the route of administration, the translational challenges associated with targeting the lung remain very difficult. In terms of testing formulations in different models, anatomical differences between mouse, ferret and human airways, including physiological size and branching complexity, impact LNP design and aerosol physics.The formulations used for mice may simply not work for people because of differences in cell composition, and lung epithelial and endothelial membranes and “surfaceomes”. As humans age and develop disease, cell protein and lipid composition may also change, requiring further optimization of LNP formulations. Mice have more narrow airways and faster breathing rates than humans, requiring smaller diameter aerosol droplets (often <2 µm) to ensure particles bypass the upper respiratory tract and reach the alveolar regions.
Moreover, humans have ~23 branches in their airways, whereas mice have only 13, meaning an aerosol optimized for a ‘deep’ reach in a mouse might only reach mid-level bronchi in a human. Furthermore, ferrets are not a widely available model system to study the biodistribution and efficacy of LNPs. Indeed, there are just a few labs in the United States that upkeep ferret colonies.
Last, a human lung’s surface area (~70 m²) is nearly 8.500 times larger than a mouse’s (~82 cm²), and human tidal volume is roughly 6,000 times greater. This requires significant dose scaling and affects how ‘diluted’ the LNPs become once they deposit.
Designing in vitro and in vivo systems representative of human biology and capable of predicting LNP biodistribution is also a tall order (especially with such a small cadre of companies working on the problem). For small molecules, the measurement of efficacy in human basal epithelium-derived patient cells carrying a mutation of interest by and large will translate into what you see in the clinic. The pharmaceutical industry has amassed a lot of data to bolster pharmacology.
Unfortunately, that correlation doesn’t necessarily hold for genetic modalities like mRNA or CRISPR/Cas9 constructs. For these medicines, it is very hard to figure out PK/PD. And so, the translation from preclinical work to the clinic can be tricky for an inhaled LNP technology delivering mRNA. It is difficult to really know the degree of protein expression from an inhaled LNP genetic medicine intracellularly without doing a bronchial biopsy (which is of course highly intrusive). And if you need to test your LNP in patients via biopsy, clinicians historically have been very resistant to carrying out such procedures, particularly in very sick patients like some of people with cystic fibrosis who carry nonsense mutations in CFTR. Thus, there is a need for alternative approaches. Certainly, there is an opportunity for more work on organoids or simpler patient cell-derived assays: 2D or 3D alternatives to large animal models like the ferret.
What is clear is that there are enough patients worldwide living with lung disease that further research in this area needs to be encouraged. In this respect, the findings from Siegwart’s group are a step in the right direction, with broad implications for treating lung diseases by enabling safer and more precise delivery of RNA-based therapeutics and genome-editing technologies.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Sian Farrell
Caitlin Dolegowski
Next Phase Newsletter 